Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Advancing Care for Patients Receiving CAR T-Cell Therapy: New Evidence and Opportunities for Oncology Pharmacy Practice

Credits Available
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: April 28, 2022 Expiration: April 27, 2023
Start Activity
Provided by ProCE, LLC in partnership with Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bristol-Myers Squibb
Craig Freyer, PharmD, BCOP
Andrew Lin, PharmD, BCOP

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate the latest clinical safety and efficacy data guiding the selection and sequencing of CAR T-cell therapy based on disease, treatment, and patient factors
  • Integrate into practice clinical trial data on CAR T-cell–based therapies for the treatment of patients with leukemia, B-cell lymphomas, or myeloma to improve outcomes and enhance survivorship
  • Manage toxicities associated with CAR T-cell therapy using available guidelines and online clinical resources and tools, and implement strategies to educate patients eligible for this treatment about the potential for these complications

Information on this Educational Activity

ProCE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Craig Freyer, PharmD, BCOP

Clinical Pharmacy Specialist
Hematology/Oncology, Stem Cell Transplant, and Cellular Therapy
Department of Pharmacy
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Craig W. Freyer, PharmD, BCOP, has disclosed that he has received consulting fees from Astellas, EUSA, and Servier.
Andrew Lin, PharmD, BCOP

Clinical Pharmacy Specialist
Adult Bone Marrow Transplant Service
Memorial Sloan Kettering Cancer Center
New York, New York

Andrew Lin, PharmD, BCOP, has disclosed that he has received consulting fees from EUSA, Incyte, and Medexus.

Staff

Jerfiz Constanzo, PhD, MBA
Scientific Director
Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Kristen Morrow, PhD

Editorial Contributor

Kristen Morrow, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

The target audience for this activity is pharmacists, including clinical, managed care, and specialty pharmacists, who care for patients with hematologic malignancies that are eligible for CAR T-cell therapy as well other stakeholders in hematology/oncology practice.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners in the management of patients with hematologic malignancies that are eligible for CAR T-cell therapy using a case-based approach with a strong focus on the thought processes needed to solve patient care problems.

Continuing Pharmacy Education

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-090-H01-P has been assigned to this home study, application-based activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 65% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 28, 2022, through April 27, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Advancing Care for Patients Receiving CAR T-Cell Therapy: New Evidence and Opportunities for Oncology Pharmacy Practice

Loading...
Watch this on-demand webcast from a recent HOPA satellite symposium on CAR T-cells for hematologic malignancies, including new data, recent approvals, and treatment guidelines.
Craig Freyer, PharmD, BCOP
Andrew Lin, PharmD, BCOP
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: April 28, 2022 Expiration: April 27, 2023

Related Content

Pharmacists review the latest findings in the treatment of relapsed/refractory multiple myeloma and provide clinical insights based on their personal experiences, from Clinical Care Options (CCO).

Rebecca Gonzalez, PharmD, BCOP Donald C. Moore, PharmD, BCPS, BCOP, DPLA Released: July 29, 2022

Downloadable slideset on advances in relapsed/refractory multiple myeloma, from ProCE, LLC in partnership with Clinical Care Options (CCO).

Rebecca Gonzalez, PharmD, BCOP Donald C. Moore, PharmD, BCPS, BCOP, DPLA Released: July 7, 2022

On-demand webcast from ProCE and Clinical Care Options (CCO), Rebecca Gonzalez, PharmD, BCOP, and Bhavesh Shah, RPh, BCOP, discuss the management of relapsed/refractory multiple myeloma

Rebecca Gonzalez, PharmD, BCOP Bhavesh Shah, RPh, BCOP Pharmacists: 1.5 contact hours (0.15 CEUs) Released: June 15, 2022 Expired: June 14, 2023

Rebecca Gonzalez, PharmD, BCOP, discusses key pharmacy strategies for management of patients with multiple myeloma in this commentary from Clinical Care Options (CCO)

Rebecca Gonzalez, PharmD, BCOP Released: May 6, 2022
Provided by ProCE, LLC in partnership with Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bristol-Myers Squibb

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings